Protective Function Of Ceruloplasmin And Its Action On Erythrocytes In Men With Prostate Tumors

Nanuli Kotrikadze, Mikheil Zibzibadze, Liana Ramishvili, Teimuraz Chigogidze, Lavrenti Managadze


Purpose: To investigate the protective action of Ceruloplasmin (Cp) on the lysis of erythrocytes in men with prostate tumors.

Material and Methods: The blood erythrocytes of the patients with benign hyperplasia of prostate (BHP) and prostate adenocarcinoma (CaP) were studied. Patients at the age 60-75 with early stages of a cancer have been investigated. The control group was consisted of apparently healthy males with the compatible age. n=15 for each group. The clinical stage of the disease was diagnosed by means of rectal, histological and echographic examination of the prostate gland. Photometric methods were applied to register lysis dynamics in order to test out the protective action of Cp.

Results: The nonspecific protective function of Cp preparation on BHP and CaP erythrocytes as well as on the control group erythrocytes was revealed. CaP erythrocytes have shown more sensitivity to the lysis provocative factor than BHP and the control group erythrocytes, that was presumably attributed to the structural and functional changes of the erythrocytes developed in the presence of malignant tumor.

Conclusion: The results show the importance of Ceruloplasmin as bioantioxidant and support the possibility of its use for therapeutic purposes, for example, in the complex course of treatment for prostate cancer.


Ceruloplasmin, Erythrocytes, Prostate, Tumors

Full Text:



Banha J., Marques L., Oliveira R., Martins Mde F., Paixão E., Pereira D., Malhó R., Penque D., Costa L.Ceruloplasmin expression by human peripheral blood lymphocytes: a new link between immunity and iron metabolism.Free Radic Biol Med. 2008. v. 44. 483-492.

Burak Çimen M.Y.Free radical metabolism in human erythrocytes.Clinica Chimica Acta. 2008. v. 390. N. 1-2. 1-11.

Cabrera A., Alonzo, E., Sauble E., Chu Y-L., Linder M. C., Sato D. S., Mason A. Z.Copper binding components of plasma and cytoplasm, copper turnover and excretion, as determined in the mouse with large doses of 65Cu. Biometals. 2008. v. 21. 525–543.

Fox P. L., Mazumder B., Ehrenwald E., Mukhopadhyay C. K.Ceruloplasmin and cardiovascular disease. Free Radical Biology and Medicine. 2000.V.28. N.12. 1735-1744.

Goryunov A.S., Sukhanova G.A., Borisova A.G. Rozhkov S.P. Trout Erythrocytes Membranes. Thermoresistivity and Thermally induced structural transitions. Jour.Therm.Anal. Calor. 2000. v. 62. 29-37.

Hellman, N.E., Gitlin, J.D.Ceruloplasmin metabolism and function. Annu. Rev. Nutr. 2002.N. 22. 439–458.

Makedou K. G., Mikhailidis D. P., Makedou A., Iliadis S., Kourtis A., Vavatsi-Christaki N., Papageorgiou G. E. Lipid Profile, Low-Density Lipoprotein Oxidation and Ceruloplasmin in the Progeny of Families With a Positive History of Cardiovascular Diseases and/or Hyperlipidemia. Angiology. 2009. N.60. 455 - 461.

Parfenov E. A., Zaikov G. E. in “Biotic Type Antioxidants: The Prospective Search Area for Novel Chemical Drugs.”VSP, 2000. 560 p.

N.E., Gaitskhoki V.S.Isolation and partial characterization of cDNA clone of human ceruloplasmin receptor.Bull Exp Biol Med. 2000.v.129.491-495.

Sato T., Orikaza M., Hasegawa H. Ceruloplasmin as an antioxidant in the serum: ability to protect glutamine synthetase under hydroxyradical generating conditions. Seikagaku. 2004.v.76. N.8. P.798.

Shukla N., Maher J., Masters J., Angelini G., Jeremy J. Does oxidative stress change ceruloplasmin from a protective to a vasculopathic factor? Atherosclerosis. 2006.v.187. Is. 2. 238-250.

Stepovaya E.A., Novitskii1V.V., Ryazantseva N.V., Gol'dberg V.E., Tkachenko S.B., Kolosova M.V.Structure and Properties of Lipid Bilayer of Erythrocyte Membranes in Patients with Malignant Tumors.Bull.Exp.Biol.Med. 2003. v.136. N.5.490-493.

Vashenko V. I.,Vashenko T. N. Ceruloplasmin — from Metalloprotein to Drug.Psychopharmacology and Biological Narcology. 2006. v. 6. N. 3. 1254- 1269.

Zhang Lan., Zhang Bai-gen., Zhang Ji-wei., Zhang Hao. Immune function of erythrocytes in patients with chronic venous insufficiency of the lower extremities.Chin. Med. Jour. 2007. v.120. 2224-2228.



  • There are currently no refbacks.

Print ISSN 1804-5804, Online ISSN 1804-9702

(c) 2018 CBU,o.p.s.